Join Edgewise’s Chief Scientific Officer and Chief Medical Officer to discuss the clinical development program for EDG-5506, a myosin modulator, that aims to prevent muscle damage in Becker and Duchenne muscular dystrophies. The webinar will highlight the mechanism of action, results from the ongoing open-label ARCH study in adults with Becker muscular dystrophy, and currently recruiting trails in Duchenne and Becker.
You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.
We use cookies to ensure that we give you the best experience on our website. By continuing to use this site you are agreeing to accept our use of cookies. For more information about cookies please visit our Privacy Policy page.I Agree